Erythropoietin is involved in angiogenesis in human primary melanoma

International Journal of Experimental Pathology

Volumn 91, Issue 6, 2010, Pages 495-499

  Ribatti, Domenico ^a   Nico, Beatrice ^a   Perra, Maria Teresa ^b   Longo, Vito ^a   Maxia, Cristina ^b   Annese, Tiziana ^a   Piras, Franca ^b   Murtas, Daniela ^b   Sirigu, Paola ^b  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Angiogenesis; Epo; EpoR; Melanoma; Tumour growth

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; MICROVASCULATURE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROPOIETIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ERYTHROPOIETIN; SKIN; SKIN NEOPLASMS;

EID: 78649515959     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2010.00731.x     Document Type: Article

References (47)

1. Acs G., Zhang P.J., Rebbeck T.R. et al. (2002) Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. Cancer 95, 969-981.
2. Acs G., Zhang P.J., McGrath C.M. et al. (2003) Hypoxia-nducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am. J. Pathol. 162, 1789-1806.
3. Arcasoy M.O., Amin K., Karayal A.F. et al. (2002) Functional significance of erythropoietin receptor expression in breast cancer. Lab. Invest. 82, 911-918.
4. Batra S., Perelman N., Luck L.R. et al. (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab. Invest. 83, 1477-1487.
5. Bayer-Graner I.B., Hough A.J., Smoller B.R. (1999) Vascular endothelial growth factor in malignant melanoma: prognostic versus diagnostic usefulness. Mod. Pathol. 12, 770-774.
6. Brennecke S., Deichmann M., Naeher H. et al. (2005) Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res. 15, 515-522.
7. Busam K.J., Berwick M., Blessing K. et al. (1995) Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am. J. Pathol. 147, 1049-1056.
8. Clark W.H., Elder D.E., Guerry D. et al. (1989) Model predicting survival in stage I melanoma based on tumor progression. J. Natl Cancer Inst. 81, 1893-1904.
9. Dillard D.G., Venkatraman G., Cohen C. et al. (2001) Immunolocalization of erythropoietin and erythropoietin receptor in vestibular schwannoma. Acta Otolaryngol. 121, 149-152.
10. Elias H., Hyde D.M. (1983) Stereological measurements of isotropic structures. In: A Guide to Practical Stereology, pp. 22-44 (eds H. Elias, D.M. Hyde ), Basel: Karger.
11. Elliott S., Lorenzini T., Chang J. et al. (1996) Fine-structure epitope mapping of anti-erythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin structure. Blood 87, 2702-2713.
12. Fairchild Benyo D., Conrad K.P. (1999) Expression of the erythropoietin receptor by throphoblast cells in human placenta. Biol. Reprod. 60, 861-870.
13. Glaspy J., Atkins M.B., Richards J.M. et al. (2009) Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalinomide in the treatment of metastatic malignant melanoma. Cancer 115, 5228-5236.
14. Hengartner M.O., Horvitz H.R. (1994) C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76, 665-676.
15. Hwu W.J., Krown S.E., Menell J.H. et al. (2003) Phase II study of temozolomide plus thalidmide for the treatment of metastatic melanoma. J. Clin. Oncol. 21, 3351-3356.
16. Isogai R., Takahashi M., Aisu K. et al. (2006) The receptor for erythropoietin is present on cutaneous mast cell. Arch. Dermatol. Res. 297, 389-394.
17. Juul S.E., Yachnis A.T., Christensen R.D. (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human foetus. Early Hum. Dev. 52, 235-249.
18. Kayser K., Gabius H.J. (1992) Analysis of expression of erythropoietin-binding sites in human lung carcinoma by the biotinylated ligand. Zentrabl. Pathol. 138, 266-270.
19. Kumar S.M., Acs G., Fang D. et al. (2005) Functional erythropoietin autocrine loop in melanoma. Am. J. Pathol. 166, 823-830.
20. Leslie M.C., Bar-Eli M. (2005) Regulation of gene expression in melanoma: new approaches for treatment. J. Cell. Biochem. 94, 25-38.
21. Li Y., Wang M.N., Li H. et al. (2002) Active immunization against the vascular endothelial growth factor flk 1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195, 1575-1584.
22. Maxwell A.P., Lappin T.R., Johnston C.F., Bridges J.M., Mc Geown M.G. (1990) Erythropoietin production in kidney tubular cells. Br. J. Haematol. 74, 535-539.
23. Meier F., Nesbit M., Hsu M.Y. et al. (2000) Human melanoma progression in skin reconstructs: biological significance of bFGF. Am. J. Pathol. 156, 193-200.
24. Mirmohammadsadegh A., Marini A., Gustrau A. et al. (2010) Role of erythropoietin receptor expression in malignant melanoma. J. Invest. Dermatol. 130, 201-210.
25. Neitzel L.T., Neitzel C.D., Magee K.L., Malafa M.P. (1999) Angiogenesis correlates with metastasis in melanoma. Ann. Surg. Oncol. 6, 70-74.
26. Niethammer A.G., Xiang R., Becker J.C. et al. (2002) A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8, 1369-1375.
27. Nurnberg W., Tobias D., Otto F. et al. (1999) Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J. Pathol. 189, 546-551.
28. Oku T., Tjuvajev J.G., Miyagawa T. et al. (1998) Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res. 58, 4185-4192.
29. Ott P.A., Chang J.L., Oratz R. et al. (2009) Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. Chemotherapy 55, 221-227.
30. Perez D.G., Suman V.J., Fitch T.R. et al. (2009) Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N047A. Cancer 115, 119-127.
31. Reed J.A., Mc Nutt N.S., Bogdany J.K., Aòlbino A.P. (1996) Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for the melanoma progression. J. Cutan. Pathol. 137, 85-92.
32. Ribatti D., Vacca A., Ria R. et al. (2002) Neovascularization, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma. Eur. J. Cancer 39, 666-674.
33. Ribatti D., Vacca A., Roccaro A.M. et al. (2003a) Erythropoietin as an angiogenic factor. Eur. J. Clin. Invest. 33, 891-896.
34. Ribatti D., Marzullo A., Nico B. et al. (2003b) Erythropoietin as an angiogenic factor in gastric carcinoma. Histopathology 42, 246-250.
35. Ribatti D., Marzullo A., Gentile A. et al. (2007a) Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 50, 591-596.
36. Ribatti D., Poliani P.L., Longo V. et al. (2007b) Erythropoietin/erythropoietin receptor system is involved in angiogenesis in human neuroblastoma. Histopathology 50, 636-641.
37. Rofstad E.K., Halsor E.F. (2000) Vascular endothelial growth factor, interleukin-8, platelet-derived endothelial growth factor and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60, 4932-4938.
38. Schulze-Osthoff K., Risau W., Vollmer E., Sorg C. (1990) In situ detection of basic fibroblast growth factor by highly specific antibodies. Am. J. Pathol. 137, 85-92.
39. Tao J., Tu Y.T., Huang C.Z. et al. (2005) Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br. J. Dermatol. 13, 715-724.
40. Ugurel S., Rappl G., Tilgen W. et al. (2000) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J. Clin. Oncol. 19, 577-583.
41. Varker K.A., Biber J.E., Kefauver C. et al. (2007) A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 14, 2367-2376.
42. Varney M.L., Johansson S.L., Singh R.K. (2006) Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125, 209-216.
43. Wedge S.R., Ogilvue D.J., Dukes M. et al. (2002) ZD 6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645-4655.
44. Westenfelder C., Baranowski R.L. (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int. 58, 647-657.
45. Yasuda Y., Musha T., Tanaka H. et al. (2001) Inhibition of erythropoietin signaling destroys xenografts of ovarian and uterine cancers in nude mice. Br. J. Cancer 84, 836-843.
46. Yasuda Y., Fujita Y., Masuda S. et al. (2002) Erythropoietin is involved in growth and angiogenesis in malignant tumors of female reproductive organs. Carcinogenesis 23, 1797-1805.
47. Yasuda Y., Fujita Y., Matsuo T. et al. (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24, 1021-1029.